Till sidinnehåll
Kunskapsbank för cancervården Till cancercentrum.se

Referenser

Abbruzzese, J. L., Lenzi, R., Raber, M. N., Pathak, S., & Frost, P. (1993). The biology of unknown primary tumors. Semin Oncol, 20(3), 238-243.

Aberg, T. (1997). Selection mechanisms as major determinants of survival after pulmonary metastasectomy. Ann Thorac Surg, 63(3), 611-612.

Acta Oncologica Symposium on Stereotactic Body Radiotherapy, June 15 – 17, 2006 Copenhagen, Denmark

Al-Brahim, N., Ross, C., Carter, B., & Chorneyko, K. (2005). The value of postmortem examination in cases of metastasis of unknown origin-20-year retrospective data from a tertiary care center. Ann Diagn Pathol, 9(2), 77-80.

Bakitas, M. A., Tosteson, T. D., Li, Z., Lyons, K. D., Hull, J. G., Li, Z., . . . Ahles, T. A. (2015). Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. J Clin Oncol, 33(13), 1438-1445. doi:10.1200/JCO.2014.58.6362

Barbosa, M., Duarte, H., Breda, E., & Monteiro, E. (2013). PET/CT in the management of metastatic cervical lymphadenopathy from unknown primary site: a seven years retrospective study. Rev Laryngol Otol Rhinol (Bord), 134(2), 89-94.

Baumann, P., Nyman, J., Hoyer, M., Gagliardi, G., Lax, I., Wennberg, B., . . . Lewensohn, R. (2008). Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol, 88(3), 359-367. doi:10.1016/j.radonc.2008.07.019

Bell, C. W., Pathak, S., & Frost, P. (1989). Unknown primary tumors: establishment of cell lines, identification of chromosomal abnormalities, and implications for a second type of tumor progression. Cancer Res, 49(15), 4311-4315.

Berger, A. K., Zschaebitz, S., Komander, C., Jager, D., & Haag, G. M. (2015). Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg. World J Gastroenterol, 21(16), 4911-4918. doi:10.3748/wjg.v21.i16.4911

Bislev, L. S., Bruun, B. J., Gregersen, S., & Knudsen, S. T. (2015). Prevalence of cancer in Danish patients referred to a fast-track diagnostic pathway is substantial. Dan Med J, 62(9).

Blomqvist L. Magnetresonanstomografi inom onkologi. Onkologi i Sverige 2009;1:37-43.

Bradley, K. A., Rubinsky, A. D., Sun, H., Bryson, C. L., Bishop, M. J., Blough, D. K., . . . Kivlahan, D. R. (2011). Alcohol screening and risk of postoperative complications in male VA patients undergoing major non-cardiac surgery. J Gen Intern Med, 26(2), 162-169. doi:10.1007/s11606-010-1475-x

Breuer, N., Behrendt, F. F., Heinzel, A., Mottaghy, F. M., Palmowski, M., & Verburg, F. A. (2014). Prognostic relevance of (18)F-FDG PET/CT in carcinoma of unknown primary. Clin Nucl Med, 39(2), 131-135. doi:10.1097/RLU.0000000000000304

Brown, P. D., Asher, A. L., & Farace, E. (2008). Adjuvant whole brain radiotherapy: strong emotions decide but rational studies are needed. Int J Radiat Oncol Biol Phys, 70(5), 1305-1309. doi:10.1016/j.ijrobp.2007.11.047

Brown, P. D., Brown, C. A., Pollock, B. E., Gorman, D. A., & Foote, R. L. (2008). Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery, 62 Suppl 2, 790-801. doi:10.1227/01.neu.0000316283.45242.e1

Bruera, E., Kuehn, N., Miller, M. J., Selmser, P., & Macmillan, K. (1991). The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care, 7(2), 6-9.

Carlson, H., Lenzi, R., Raber, M. N., & Varadhachary, G. R. (2013). A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary. Int J Clin Oncol, 18(2), 226-231. doi:10.1007/s10147-011-0366-4

Chen, K. T., & Flam, M. S. (1986). Peritoneal papillary serous carcinoma with long-term survival. Cancer, 58(6), 1371-1373.

Culine, S., Kramar, A., Saghatchian, M., Bugat, R., Lesimple, T., Lortholary, A., . . . French Study Group on Carcinomas of Unknown, P. (2002). Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol, 20(24), 4679-4683.

Dawson, L. A., & Ten Haken, R. K. (2005). Partial volume tolerance of the liver to radiation. Semin Radiat Oncol, 15(4), 279-283. doi:10.1016/j.semradonc.2005.04.005

Delaney, G., Jacob, S., & Barton, M. (2006). Estimating the optimal radiotherapy utilization for carcinoma of the central nervous system, thyroid carcinoma, and carcinoma of unknown primary origin from evidence-based clinical guidelines. Cancer, 106(2), 453-465. doi:10.1002/cncr.21596

Deonarine, P., Han, S., Poon, F. W., & de Wet, C. (2013). The role of 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the management of patients with carcinoma of unknown primary. Scott Med J, 58(3), 154-162. doi:10.1177/0036933013496958

Dong, M. J., Zhao, K., Lin, X. T., Zhao, J., Ruan, L. X., & Liu, Z. F. (2008). Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature. Nucl Med Commun, 29(9), 791-802. doi:10.1097/MNM.0b013e328302cd26

Ellerbroek, N., Holmes, F., Singletary, E., Evans, H., Oswald, M., & McNeese, M. (1990). Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer, 66(7), 1461-1467.

Fearon, K., Strasser, F., Anker, S. D., Bosaeus, I., Bruera, E., Fainsinger, R. L., . . . Baracos, V. E. (2011). Definition and classification of cancer cachexia: an international consensus. Lancet Oncol, 12(5), 489-495. doi:10.1016/S1470-2045(10)70218-7

Fizazi, K., Committee, o. b. o. t. E. G., Greco, F. A., Committee, o. b. o. t. E. G., Pavlidis, N., Committee, o. b. o. t. E. G., . . . Committee, o. b. o. t. E. G. (2015). Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of Oncology, 26(suppl_5), v133-v138. doi:10.1093/annonc/mdv305 %J Annals of Oncology

Foulds, L. (1958). The natural history of cancer. J Chronic Dis, 8(1), 2-37.

Frazier, S. R., Kaplan, P. A., & Loy, T. S. (2007). The pathology of extrapulmonary small cell carcinoma. Semin Oncol, 34(1), 30-38. doi:10.1053/j.seminoncol.2006.11.017

Friedel, G., Pastorino, U., Buyse, M., Ginsberg, R. J., Girard, P., Goldstraw, P., . . . Toomes, H. (1999). [Resection of lung metastases: long-term results and prognostic analysis based on 5206 cases--the International Registry of Lung Metastases]. Zentralbl Chir, 124(2), 96-103.

Fritzson, A., Tavelin, B., & Axelsson, B. (2015). Association between parenteral fluids and symptoms in hospital end-of-life care: an observational study of 280 patients. BMJ Support Palliat Care, 5(2), 160-168. doi:10.1136/bmjspcare-2013-000501

Frost P, Raber MN, Abbruzzese JL, Unknown primary tumors as a unique clinical and biological entity: a hypothesis. Cancer Bulletin Cancer Bull 1989; 41:139-141.

Furmaniak, A. C., Menig, M., & Markes, M. H. (2016). Exercise for women receiving adjuvant therapy for breast cancer. Cochrane Database Syst Rev, 9, Cd005001. doi:10.1002/14651858.CD005001.pub3

Greco F, Culine S. Chemotherapy for patients with metastatic carcinoma of unknown primary site. Kapitel 8 i Cancer of an unknown primary site (Fizazi K, red). Taylor &Francis, New York – London 2006.

Gunven, P., Blomgren, H., Lax, I., & Levitt, S. H. (2009). Curative stereotactic body radiotherapy for liver malignancy. Med Oncol, 26(3), 327-334. doi:10.1007/s12032-008-9125-4

Hainsworth J. Treatment of patients with favorable subsets of unknown primary carcinoma. Kapitel 7 i Fizazi K (redaktör): Cancer of an unknown primary site. Taylor &Francis, New York – Lodon 2006.

Hainsworth, J. D., & Greco, F. A. (2018). Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine. Am Soc Clin Oncol Educ Book, 38, 20-25. doi:10.1200/edbk_100014

Hainsworth, J. D., Spigel, D. R., Farley, C., Thompson, D. S., Shipley, D. L., Greco, F. A., & Minnie Pearl Cancer Research, N. (2007). Phase II trial of bevacizumab and erlotinib in carcinomas of unknown primary site: the Minnie Pearl Cancer Research Network. J Clin Oncol, 25(13), 1747-1752. doi:10.1200/JCO.2006.09.3047

Han, A., Xue, J., Hu, M., Zheng, J., & Wang, X. (2012). Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary. Cancer Epidemiol, 36(5), 470-475. doi:10.1016/j.canep.2012.03.002

Hayashi, H., Kurata, T., Takiguchi, Y., Arai, M., Takeda, K., Akiyoshi, K., . . . Nakagawa, K. (2019). Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site. J Clin Oncol, 37(7), 570-579. doi:10.1200/jco.18.00771

Hirashima, T., Nagai, T., Shigeoka, H., Tamura, Y., Yoshida, H., Kawahara, K., . . . Kawase, I. (2014). Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study. BMC Cancer, 14, 770. doi:10.1186/1471-2407-14-770

Horlings, H. M., van Laar, R. K., Kerst, J. M., Helgason, H. H., Wesseling, J., van der Hoeven, J. J., . . . de Jong, D. (2008). Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol, 26(27), 4435-4441. doi:10.1200/JCO.2007.14.6969

Huebner, G., Link, H., Kohne, C. H., Stahl, M., Kretzschmar, A., Steinbach, S., . . . German, C. U. P. S. G. (2009). Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial. Br J Cancer, 100(1), 44-49. doi:10.1038/sj.bjc.6604818

Husemann, Y., Geigl, J. B., Schubert, F., Musiani, P., Meyer, M., Burghart, E., . . . Klein, C. A. (2008). Systemic spread is an early step in breast cancer. Cancer Cell, 13(1), 58-68. doi:10.1016/j.ccr.2007.12.003

Hylton, N. (2005). Magnetic resonance imaging of the breast: opportunities to improve breast cancer management. J Clin Oncol, 23(8), 1678-1684. doi:10.1200/JCO.2005.12.002

Hyphantis, T., Papadimitriou, I., Petrakis, D., Fountzilas, G., Repana, D., Assimakopoulos, K., . . . Pavlidis, N. (2013). Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site. Psychooncology, 22(9), 2009-2015. doi:10.1002/pon.3244

Iwakawa, M., Noda, S., Yamada, S., Yamamoto, N., Miyazawa, Y., Yamazaki, H., . . . Imai, T. (2006). Analysis of non-genetic risk factors for adverse skin reactions to radiotherapy among 284 breast cancer patients. Breast Cancer, 13(3), 300-307.

Jackson, B., Scott-Conner, C., & Moulder, J. (1995). Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surg, 61(5), 431-434.

Jagsi, R., Griffith, K. A., Koelling, T., Roberts, R., & Pierce, L. J. (2007). Rates of myocardial infarction and coronary artery disease and risk factors in patients treated with radiation therapy for early-stage breast cancer. Cancer, 109(4), 650-657. doi:10.1002/cncr.22452

Johnson, M., Tod, A. M., Brummell, S., & Collins, K. (2015). Prognostic communication in cancer: A critical interpretive synthesis of the literature. Eur J Oncol Nurs, 19(5), 554-567. doi:10.1016/j.ejon.2015.03.001

Kaaks, R., Sookthai, D., Hemminki, K., Kramer, A., Boeing, H., Wirfalt, E., . . . Canzian, F. (2014). Risk factors for cancers of unknown primary site: Results from the prospective EPIC cohort. Int J Cancer, 135(10), 2475-2481. doi:10.1002/ijc.28874

Karapolat, I., & Kumanlioglu, K. (2012). Impact of FDG-PET/CT for the Detection of Unknown Primary Tumours in Patients with Cervical Lymph Node Metastases. Mol Imaging Radionucl Ther, 21(2), 63-68. doi:10.4274/Mirt.344

Karsell, P. R., Sheedy, P. F., 2nd, & O'Connell, M. J. (1982). Computed tomography in search of cancer of unknown origin. JAMA, 248(3), 340-343.

Katoh, N., Onimaru, R., Sakuhara, Y., Abo, D., Shimizu, S., Taguchi, H., . . . Shirato, H. (2008). Real-time tumor-tracking radiotherapy for adrenal tumors. Radiother Oncol, 87(3), 418-424. doi:10.1016/j.radonc.2008.03.013

Kaufman, E. L., Jacobson, J. S., Hershman, D. L., Desai, M., & Neugut, A. I. (2008). Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol, 26(3), 392-398. doi:10.1200/JCO.2007.13.3033

Keulers, B. J., Scheltinga, M. R., Houterman, S., Van Der Wilt, G. J., & Spauwen, P. H. (2008). Surgeons underestimate their patients' desire for preoperative information. World J Surg, 32(6), 964-970. doi:10.1007/s00268-008-9581-1

Kim, M. K., Sim, J. A., Yun, Y. H., Bae, D. S., Nam, J. H., Park, C. T., . . . Park, S. Y. (2016). Health-Related Quality of Life and Sociodemographic Characteristics as Prognostic Indicators of Long-term Survival in Disease-Free Cervical Cancer Survivors. Int J Gynecol Cancer, 26(4), 743-749. doi:10.1097/igc.0000000000000665

Koong, H. N., Pastorino, U., & Ginsberg, R. J. (1999). Is there a role for pneumonectomy in pulmonary metastases? International Registry of Lung Metastases. Ann Thorac Surg, 68(6), 2039-2043.

Kwee, T. C., & Kwee, R. M. (2009). Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis. Eur Radiol, 19(3), 731-744. doi:10.1007/s00330-008-1194-4

Kwee, T. C., Takahara, T., Ochiai, R., Nievelstein, R. A., & Luijten, P. R. (2008). Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol, 18(9), 1937-1952. doi:10.1007/s00330-008-0968-z

Lauenstein, T. C., Ajaj, W., Narin, B., Gohde, S. C., Kroger, K., Debatin, J. F., & Ruhm, S. G. (2005). MR imaging of apparent small-bowel perfusion for diagnosing mesenteric ischemia: feasibility study. Radiology, 234(2), 569-575. doi:10.1148/radiol.2342031002

Lee, J. R., Kim, J. S., Roh, J. L., Lee, J. H., Baek, J. H., Cho, K. J., . . . Kim, S. Y. (2015). Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study. Radiology, 274(3), 764-771. doi:10.1148/radiol.14141073

Lesimple T, Balana C. Carcinoma of unknown primary in a single site. Kapitel 12 I Fizazi K (redaktör): Cancer of an unknown primary site.     Taylor &Francis, New York – London 2006.

Lithner, M. and T. Zilling, Does preoperative information increase the wellbeing of the patient after surgery? (in Swedish). Vård i Norden 1998; 18:31-33,39.

Macdonald, G., Kondor, N., Yousefi, V., Green, A., Wong, F., & Aquino-Parsons, C. (2004). Reduction of carboxyhaemoglobin levels in the venous blood of cigarette smokers following the administration of carbogen. Radiother Oncol, 73(3), 367-371. doi:10.1016/j.radonc.2004.09.002

Maiche, A. G. (1993). Cancer of unknown primary. A retrospective study based on 109 patients. Am J Clin Oncol, 16(1), 26-29.

Milano, M. T., Katz, A. W., Schell, M. C., Philip, A., & Okunieff, P. (2008). Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys, 72(5), 1516-1522. doi:10.1016/j.ijrobp.2008.03.044

Milovic, M., Popov, I., & Jelic, S. (2002). Tumor markers in metastatic disease from cancer of unknown primary origin. Med Sci Monit, 8(2), MT25-30.

Molina, R., Bosch, X., Auge, J. M., Filella, X., Escudero, J. M., Molina, V., . . . Lopez-Soto, A. (2012). Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site. Tumour Biol, 33(2), 463-474. doi:10.1007/s13277-011-0275-1

Moller, A. K., Pedersen, K. D., Abildgaard, J., Petersen, B. L., & Daugaard, G. (2010). Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site. Acta Oncol, 49(4), 431-435. doi:10.3109/02841861003649240

Moller, T. R., Brorsson, B., Ceberg, J., Frodin, J. E., Lindholm, C., Nylen, U., . . . Group, S. B. U. S. (2003). A prospective survey of radiotherapy practice 2001 in Sweden. Acta Oncol, 42(5-6), 387-410.

Naresh, K. N. (2002). Do metastatic tumours from an unknown primary reflect angiogenic incompetence of the tumour at the primary site?--a hypothesis. Med Hypotheses, 59(3), 357-360.

Nath, B., Li, Y., Carroll, J. E., Szabo, G., Tseng, J. F., & Shah, S. A. (2010). Alcohol exposure as a risk factor for adverse outcomes in elective surgery. J Gastrointest Surg, 14(11), 1732-1741. doi:10.1007/s11605-010-1350-4

Nationellt vårdprogram palliativ vård

Norihisa, Y., Nagata, Y., Takayama, K., Matsuo, Y., Sakamoto, T., Sakamoto, M., . . . Hiraoka, M. (2008). Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys, 72(2), 398-403. doi:10.1016/j.ijrobp.2008.01.002

Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol, 5(6), 649-655.

Orel, S. (2008). Who should have breast magnetic resonance imaging evaluation? J Clin Oncol, 26(5), 703-711. doi:10.1200/JCO.2007.14.3594

Pastorino, U., Buyse, M., Friedel, G., Ginsberg, R. J., Girard, P., Goldstraw, P., . . . International Registry of Lung, M. (1997). Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg, 113(1), 37-49.

Patientlag (2014:821) 3:e och 4:e kapitlet

Pavlidis, N. (2007). Forty years experience of treating cancer of unknown primary. Acta Oncol, 46(5), 592-601. doi:10.1080/02841860701243095

Pavlidis, N., Briasoulis, E., Hainsworth, J., & Greco, F. A. (2003). Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer, 39(14), 1990-2005.

Pavlidis, N., Kalef-Ezra, J., Briassoulis, E., Skarlos, D., Kosmidis, P., Saferiadis, K., . . . et al. (1994). Evaluation of six tumor markers in patients with carcinoma of unknown primary. Med Pediatr Oncol, 22(3), 162-167.

Pavlidis, N., Rassy, E., & Smith-Gagen, J. Cancer of unknown primary: Incidence rates, risk factors and survival among adolescents and young adults. 0(0). doi:10.1002/ijc.32482

Pentheroudakis, G., Stoyianni, A., & Pavlidis, N. (2011). Cancer of unknown primary patients with midline nodal distribution: midway between poor and favourable prognosis? Cancer Treat Rev, 37(2), 120-126. doi:10.1016/j.ctrv.2010.06.003

Petru, E., Benedicic, C., Seewann, A., & Pickel, H. (2003). Palliative cytostatic treatment of cervical carcinoma. Eur J Gynaecol Oncol, 24(6), 473-474.

Prochazka, M., Granath, F., Ekbom, A., Shields, P. G., & Hall, P. (2002). Lung cancer risks in women with previous breast cancer. Eur J Cancer, 38(11), 1520-1525.

Prowse, S. J., Shaw, R., Ganeshan, D., Prowse, P. M., Hanlon, R., Lewis-Jones, H., & Wieshmann, H. (2013). The added value of 18F-fluorodeoxyglucose positron emission tomography computed tomography in patients with neck lymph node metastases from an unknown primary malignancy. J Laryngol Otol, 127(8), 780-787. doi:10.1017/S002221511300162X

Rades, D., Bohlen, G., Lohynska, R., Veninga, T., Stalpers, L. J., Schild, S. E., & Dunst, J. (2007). Whole-brain radiotherapy with 20 Gy in 5 fractions for brain metastases in patients with cancer of unknown primary (CUP). Strahlenther Onkol, 183(11), 631-636. doi:10.1007/s00066-007-1763-5

Rades, D., Fehlauer, F., Veninga, T., Stalpers, L. J., Basic, H., Hoskin, P. J., . . . Dunst, J. (2007). Functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary. Int J Radiat Oncol Biol Phys, 67(2), 532-537. doi:10.1016/j.ijrobp.2006.08.047

Randen, M., Helde-Frankling, M., Runesdotter, S., & Gunven, P. (2013). Unfavorable cancers of unknown primaries: presentation and prognostic factors. A population-based 8-year experience. Med Oncol, 30(4), 706. doi:10.1007/s12032-013-0706-5

Randen, M., Rutqvist, L. E., & Johansson, H. (2009). Cancer patients without a known primary: incidence and survival trends in Sweden 1960-2007. Acta Oncol, 48(6), 915-920. doi:10.1080/02841860902862503

Ransom, D. T., Patel, S. R., Keeney, G. L., Malkasian, G. D., & Edmonson, J. H. (1990). Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy. Cancer, 66(6), 1091-1094.

Schelfout, K., Kersschot, E., Van Goethem, M., Thienpont, L., Van den Haute, J., Roelstraete, A., & De Schepper, A. (2003). Breast MR imaging in a patient with unilateral axillary lymphadenopathy and unknown primary malignancy. Eur Radiol, 13(9), 2128-2132. doi:10.1007/s00330-002-1674-x

Schlemmer, H. P., Schafer, J., Pfannenberg, C., Radny, P., Korchidi, S., Muller-Horvat, C., . . . Claussen, C. D. (2005). Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: initial experiences. Invest Radiol, 40(2), 64-71.

Schorn, C., Fischer, U., Luftner-Nagel, S., Westerhof, J. P., & Grabbe, E. (1999). MRI of the breast in patients with metastatic disease of unknown primary. Eur Radiol, 9(3), 470-473. doi:10.1007/s003300050694

Sharp, L., Johansson, H., Hatschek, T., & Bergenmar, M. (2013). Smoking as an independent risk factor for severe skin reactions due to adjuvant radiotherapy for breast cancer. Breast, 22(5), 634-638. doi:10.1016/j.breast.2013.07.047

Shaw, P. H., Adams, R., Jordan, C., & Crosby, T. D. (2007). A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clin Oncol (R Coll Radiol), 19(1), 87-95.

Socialstyrelsen. Nationellt kunskapsstöd för god palliativ vård i livets slutskede. 

Statistikdatabasen. (2019-05-27). Retrieved from https://www.socialstyrelsen.se/statistik-och-data/statistik/statistikdatabasen/

Sundin A, Berglund Å. Radiological assessment. I Metastatic Carcinomas of Unknown Origin. (Wick, red.).  Demos Medical Publishing, USA, 2008.

Svedman, C., Karlsson, K., Rutkowska, E., Sandstrom, P., Blomgren, H., Lax, I., & Wersall, P. (2008). Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol, 47(8), 1578-1583. doi:10.1080/02841860802123196

Swift, P. S. (2009). Radiation for spinal metastatic tumors. Orthop Clin North Am, 40(1), 133-144, vii. doi:10.1016/j.ocl.2008.09.001

Tamam, M. O., Mulazimoglu, M., Guveli, T. K., Tamam, C., Eker, O., & Ozpacaci, T. (2012). Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin. Eur Rev Med Pharmacol Sci, 16(15), 2120-2130.

Tao, L., Yu, H., Dong, Y., Tian, G., Ren, Z., & Li, D. (2019). Metastases with definitive pathological diagnosis but no detectable primary tumor: A surveillance epidemiology and end results-based study. 8(13), 5872-5880. doi:10.1002/cam4.2496

Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., . . . Lynch, T. J. (2010). Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med, 363(8), 733-742. doi:10.1056/NEJMoa1000678

Tonnesen, H., Nielsen, P. R., Lauritzen, J. B., & Moller, A. M. (2009). Smoking and alcohol intervention before surgery: evidence for best practice. Br J Anaesth, 102(3), 297-306. doi:10.1093/bja/aen401

Treasure, T. (2007). Pulmonary metastasectomy: a common practice based on weak evidence. Ann R Coll Surg Engl, 89(8), 744-748. doi:10.1308/003588407X232198

van de Wouw, A. J., Jansen, R. L., Speel, E. J., & Hillen, H. F. (2003). The unknown biology of the unknown primary tumour: a literature review. Ann Oncol, 14(2), 191-196.

van der Gaast, A., Verweij, J., Henzen-Logmans, S. C., Rodenburg, C. J., & Stoter, G. (1990). Carcinoma of unknown primary: identification of a treatable subset? Ann Oncol, 1(2), 119-122.

Wang, G., Wu, Y., Zhang, W., Li, J., Wu, P., & Xie, C. (2013). Clinical value of whole-body F-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with carcinoma of unknown primary. J Med Imaging Radiat Oncol, 57(1), 65-71. doi:10.1111/j.1754-9485.2012.02441.x

Varadhachary, G. R., Raber, M. N., Matamoros, A., & Abbruzzese, J. L. (2008). Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol, 9(6), 596-599. doi:10.1016/S1470-2045(08)70151-7

Varadhachary, G. R., Talantov, D., Raber, M. N., Meng, C., Hess, K. R., Jatkoe, T., . . . Hainsworth, J. D. (2008). Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol, 26(27), 4442-4448. doi:10.1200/JCO.2007.14.4378

Wells, M., Macmillan, M., Raab, G., MacBride, S., Bell, N., MacKinnon, K., . . . Munro, A. (2004). Does aqueous or sucralfate cream affect the severity of erythematous radiation skin reactions? A randomised controlled trial. Radiother Oncol, 73(2), 153-162. doi:10.1016/j.radonc.2004.07.032

Wong, W. L., Sonoda, L. I., Gharpurhy, A., Gollub, F., Wellsted, D., Goodchild, K., . . . Saunders, M. (2012). 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of occult primary head and neck cancers--an audit and review of published studies. Clin Oncol (R Coll Radiol), 24(3), 190-195. doi:10.1016/j.clon.2011.11.001

www.palliativregistret.se/.

Väntetider i vården. Retrieved from https://www.vantetider.se/

Yoon, Y. J., Ahn, S. H., Park, J. Y., Chon, C. Y., Kim do, Y., Park, Y. N., & Han, K. H. (2007). What is the role of diagnostic laparoscopy in a gastroenterology unit? J Gastroenterol, 42(11), 881-886. doi:10.1007/s00535-007-2106-0

Zivanovic, O., Sonoda, Y., Diaz, J. P., Levine, D. A., Brown, C. L., Chi, D. S., . . . Abu-Rustum, N. R. (2008). The rate of port-site metastases after 2251 laparoscopic procedures in women with underlying malignant disease. Gynecol Oncol, 111(3), 431-437. doi:10.1016/j.ygyno.2008.08.024

Nästa kapitel
17 Vårdprogramgruppen